Jonathan Tolins, MD
Nephrology · Edina, MNNPI 1194830463
Payments from drug & device makers
Across 418 payments — averaging $7972.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vertex$1.2M
- AstraZeneca$774K
- Beigene, Ltd.$328K
- Novartis$189K
- Beone Medicines Ltd.$166K
- CSL Behring$163K
- plus $551K from 11 others
Across 14 payments — averaging $1127.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Travere Therapeutics, Inc.$16K
What the payments were for
- Travel & lodging$7,83273%
- Food & beverage$2,87927%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vertex | 8 | $1,163,077 |
| AstraZeneca(2 entities) | 39 | $773,671 |
| Beigene, Ltd. | 29 | $327,774 |
| Novartis | 6 | $188,836 |
| Beone Medicines Ltd. | 6 | $165,729 |
| CSL Behring | 58 | $162,792 |
| Astrazeneca UK Limited | 10 | $121,481 |
| Alnylam Pharmaceuticals Inc. | 39 | $109,506 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $98,339 |
| Boehringer Ingelheim International GmbH | 4 | $82,152 |
| Akebia Therapeutics Inc | 93 | $33,915 |
| Bayer | 29 | $33,813 |
| Travere Therapeutics, Inc. | 33 | $29,015 |
| Beigene USA, Inc. | 17 | $23,577 |
| Dynavax Technologies Corporation | 29 | $16,578 |
| Merck | 14 | $2,286 |
| Astellas Pharma US Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,332,555 in reported general payments places this provider in the 95th percentile of 208 nephrology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 25 | $25,729 |
| Sodium Chloride0.9 % Sodium Chloride | 35 | $1,817 |
| Calcium Acetate | 21 | $1,770 |
| Lisinopril | 49 | $950 |
| Allopurinol | 37 | $642 |
| Losartan Potassium | 32 | $591 |
| Furosemide | 56 | $441 |
| Amlodipine Besylate | 30 | $417 |
| Carvedilol | 22 | $343 |
| Torsemide | 11 | $197 |
| Hydrochlorothiazide | 14 | $64 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Edina
- Mark MatsonSt. Paul$6.3M
- Daniel RiesBrooklyn Center$4.4M
- John LieskeRochester$2.4M
- George CanasBrooklyn Center$2.1M
- Suzanne SwanMinneapolis$2.1M
- Fernando FervenzaRochester$1.7M
- Nattawat KlomjitRochester$1.5M
- Neera DahlRochester$1.4M
- Vicente TorresRochester$661K
- Jeffrey ConnaireMinneapolis$638K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.